Total Payments
$30,405
2024 Payments
$15,915
Companies
12
Transactions
66
Medicare Patients
1,480
Medicare Billing
$175,537
Payment Breakdown by Category
Other$24,135 (79.4%)
Travel$2,906 (9.6%)
Food & Beverage$1,396 (4.6%)
Consulting$1,130 (3.7%)
Research$809.86 (2.7%)
Education$28.77 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,135 | 17 | 79.4% |
| Travel and Lodging | $2,906 | 15 | 9.6% |
| Food and Beverage | $1,396 | 26 | 4.6% |
| Consulting Fee | $1,130 | 1 | 3.7% |
| Unspecified | $809.86 | 3 | 2.7% |
| Education | $28.77 | 4 | 0.1% |
Payments by Type
General
$29,595
63 transactions
Research
$809.86
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $15,915 | 24 | $0 (2024) |
| Biogen, Inc. | $12,132 | 15 | $0 (2022) |
| Eisai Inc. | $1,045 | 14 | $0 (2019) |
| Eli Lilly and Company | $809.86 | 3 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $113.88 | 1 | $0 (2018) |
| Genentech USA, Inc. | $112.81 | 1 | $0 (2017) |
| Mitsubishi Tanabe Pharma America, Inc. | $88.89 | 1 | $0 (2018) |
| PFIZER INC. | $68.00 | 1 | $0 (2017) |
| ABBVIE INC. | $40.19 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $37.57 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,915 | 24 | Lilly USA, LLC ($15,915) |
| 2023 | $318.46 | 2 | Eli Lilly and Company ($305.00) |
| 2022 | $612.72 | 6 | Eli Lilly and Company ($450.00) |
| 2021 | $10,896 | 11 | Biogen, Inc. ($10,839) |
| 2020 | $1,168 | 3 | Biogen, Inc. ($1,130) |
| 2019 | $982.41 | 14 | Eisai Inc. ($970.38) |
| 2018 | $257.63 | 3 | Teva Pharmaceuticals USA, Inc. ($113.88) |
| 2017 | $255.06 | 3 | Genentech USA, Inc. ($112.81) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $101.84 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $7.81 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $0.76 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $106.53 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 10/17/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $102.50 | General |
| Category: Neuroscience | ||||||
| 10/17/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $36.87 | General |
| Category: Neuroscience | ||||||
| 10/17/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $24.61 | General |
| Category: Neuroscience | ||||||
| 10/14/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 10/14/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 10/10/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Neuroscience | ||||||
| 09/19/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,400.00 | General |
| Category: Neuroscience | ||||||
| 09/12/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $434.16 | General |
| 09/12/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $323.94 | General |
| 09/12/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $207.88 | General |
| 09/12/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $205.38 | General |
| 04/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $733.41 | General |
| 04/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $92.63 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $305.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $450.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $305.00 | 1 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $54.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 174 | 181 | $72,464 | $13,563 |
| 2022 | 5 | 417 | 461 | $178,211 | $38,862 |
| 2021 | 7 | 427 | 4,714 | $214,232 | $61,890 |
| 2020 | 9 | 462 | 5,543 | $240,691 | $61,222 |
Total Patients
1,480
Total Services
10,899
Medicare Billing
$175,537
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 67 | $24,098 | $4,478 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 39 | $19,311 | $3,749 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 28 | $12,225 | $2,110 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 35 | $10,290 | $2,065 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $6,540 | $1,160 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 136 | $48,344 | $10,919 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 62 | 70 | $30,613 | $7,031 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 86 | 100 | $29,488 | $6,499 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 39 | $19,816 | $3,624 | 18.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $12,990 | $2,779 | 21.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 32 | 32 | $12,957 | $2,548 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $8,715 | $2,291 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $9,810 | $2,115 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 21 | $5,478 | $1,057 | 19.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 11 | 4,235 | $63,860 | $19,721 | 30.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 102 | 122 | $37,906 | $10,164 | 26.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 69 | 79 | $24,616 | $7,885 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 110 | $25,870 | $7,044 | 27.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 43 | 52 | $20,368 | $6,646 | 32.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 36 | 36 | $13,080 | $3,191 | 24.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $10,670 | $3,074 | 28.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 28 | $6,868 | $1,747 | 25.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $7,200 | $1,693 | 23.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 12 | 14 | $3,794 | $725.69 | 19.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 11 | 5,050 | $75,994 | $24,146 | 31.8% |
About Dr. David Hart, MD
Dr. David Hart, MD is a Neurology healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245289990.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Hart, MD has received a total of $30,405 in payments from pharmaceutical and medical device companies, with $15,915 received in 2024. These payments were reported across 66 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($24,135).
As a Medicare-enrolled provider, Hart has provided services to 1,480 Medicare beneficiaries, totaling 10,899 services with total Medicare billing of $175,537. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Albany, NY
- Active Since 05/09/2006
- Last Updated 11/06/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1245289990
Products in Payments
- KISUNLA (Drug) $13,918
- ADUHELM (Biological) $237.99
- AJOVY (Drug) $113.88
- Non-Covered Product (Drug) $112.81
- Radicava (Drug) $88.89
- ZEPOSIA (Drug) $37.57
- Aimovig (Biological) $30.07
- PLEGRIDY (Biological) $28.77
- UBRELVY (Drug) $26.73
- QULIPTA (Drug) $13.46
- GILENYA (Drug) $12.03
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Albany
Charles Argoff, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Mrs. Angela Applebee, M.d, M.D
Neurology — Payments: $690,780
Neurology $690,780
Dr. Krupa Pandey, M.d, M.D
Neurology — Payments: $611,544
Neurology $611,544
Dr. Stanley Penc, Md Phd, MD PHD
Neurology — Payments: $552,076
Neurology $552,076
Dr. Timothy Lynch, Md, MD
Neurology — Payments: $273,946
Neurology $273,946
Dr. Jennifer Durphy, M.d, M.D
Neurology — Payments: $117,071
Neurology $117,071